Shield Therapeutics’ (STX) “Buy” Rating Reiterated at Peel Hunt

Peel Hunt restated their buy rating on shares of Shield Therapeutics (LON:STX) in a research note published on Wednesday, MarketBeat.com reports. They currently have a GBX 15 price target on the stock.

Shield Therapeutics Price Performance

Shield Therapeutics stock opened at GBX 7.80 on Wednesday. The firm has a market capitalization of £81.25 million, a PE ratio of -390.00 and a beta of 1.42. The company’s 50-day moving average is GBX 6.73 and its 200-day moving average is GBX 4.12. Shield Therapeutics has a fifty-two week low of GBX 2.10 and a fifty-two week high of GBX 9.10. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.